InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 277153

Tuesday, 10/25/2016 5:15:43 AM

Tuesday, October 25, 2016 5:15:43 AM

Post# of 345700
CP, regarding the non-blinded data being combined with blinded data...I wonder if it would be possible if later they somehow find a biomarker within the blinded data alone and no need to combine with the non-blinded data ...IF that would make a difference to be used to file with the FDA ....but I still think no matter what, that this all has to do with allowing some new partner have their wish with whatever combo best suits them.

Anyhow... I have a little theory regarding the LinkedIn initiative to "close the door" so to speak on being able to view all those that follow a company and remember, in a world of transparency where Facebook meets LinkedIn and the goal is to let the world in to view all....this closing of the door to seeing followers never made sense to me.....

But I do see that "Reid Hoffman" CEO of LinkedIn was supposed to be the primary 10% outside investor of Facebook and he turned it down and referred Sean Parker to his friend ....guess who??

Peter Thiel

I have some new theories now and all these billionaires in the room making me think they certainly are not going to just let PS Targeting pass them by and a coincidence that Peter Thiel gets in with Robert Garnick at Stemcentrx


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News